drugset / Trial / NCT04219319
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma
Phase 1
Terminated
4 enrolled
The First Affiliated Hospital with Nanjing Medical University
Nanjing Legend Biotechnology Co. The First Affiliated Hospital of USTC west district；The First Affiliated Hospital of the Air Force Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
A Phase I, Multicenter study to evaluate the safety, tolerability, and Efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+T Lymphocyte Tumor Patients.
Timeline
- Start
- 2021-12-15
- Primary completion
- 2022-07-20
- Completion
- 2022-07-20
Outcome
Outcome not reported
Stopped: “Both the sponsors and collaborator are considering terminating the study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCAR-T2C | Cell therapy | — | Other |